AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc. LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of...

AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema LOUISVILLE, Colo., Oct. 17, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing therapies to address significant...

AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors LOUISVILLE, Colo., Oct. 09, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company specializing in the development of innovative drug...

AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board LOUISVILLE, Colo., Oct. 04, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“The Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing platform technologies to target significant unmet...

AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors LOUISVILLE, Colo., Aug. 07, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio”) (OTCQB:ANTB) and ActiveSite Pharmaceuticals (“ActiveSite”) today announced that AntriaBio has exclusively licensed...